Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II).
Pablo Hernáiz Driever, Uwe R Kordes, Ines B Brecht, Veronica Saletti, Michael J Fisher, Gail Doughton, Million Arefayene, Anna Rigazio, Nuria Lluch, Nereida Llorente, Scott J Diede, Hector Salvador
Published: 202610.1200/JCO-25-01447
Abstract
PURPOSE: Neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN) can substantially affect quality of life. The capsule and granule formulations of selumetinib (ARRY-142886, AZD6244) are approved for pediatric patients with symptomatic,…
Preview only. Read the full abstract at the source